In the pursuit of the most advanced vaccines of high potential, the board of Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using mRNA, the next generation vaccine technology. The technology enables development synergies with other vaccine candidates in our portfolio, gaining competitive edge with less investments. At the same time, the company decides to pause the resource-intensive development of the protein-based chlamydia candidate until further notice.

The success of mRNA vaccines in the Covid pandemic has fundamentally changed the way vaccines are developed. Being at the forefront in vaccine development, Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using the modern mRNA technology. The goal is to conduct preclinical studies and early mRNA development in the near term, to begin process development and other preparations in the fourth quarter of 2023, ahead of toxicological and then clinical trials. The resource-intensive development of the protein-based chlamydia vaccine candidate will be paused until further notice.

“mRNA-based vaccines have shown great clinical potential to drive both antibodies and T-cells, which is exactly what we aim for with our chlamydia vaccine. In addition, we see good opportunities to achieve synergies between our portfolio projects which use the same platform technology.” says Dr. Karl Ljungberg, Head of Preclinical Development at Eurocine Vaccines.

The mRNA-based vaccine candidate against chlamydia encodes for the same protein that has earlier been successfully documented and is covered by the same patent and exclusive global licensing agreement.  This strengthens the conditions for success with the mRNA candidate.

This information is such information that Eurocine Vaccines AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 17 January 2023.